期刊
CARDIOVASCULAR RESEARCH
卷 82, 期 3, 页码 468-475出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvp091
关键词
Valsartan; PI3K; Src family kinase; AT(1)R; eNOS
资金
- National Scientific Council [NSC-95-2320-B-001-039-MY3, NSC-96-2320-B-010-031-MY3]
- National Health Research Institutes [NHRI-EX97-9608SC]
- VGHUST Joint Research Program, Tsou's Foundation [VGHUST 96-P7-33, 97-P6-27]
- Department of Health of Taipei City Government [97001-62-016]
Valsartan, a selective angiotensin II type 1 receptor (AT(1)R) blocker, has beneficial effects in the cardiovascular system in part by its increase of nitric oxide (NO) bioavailability, yet the mechanisms are unclear. We investigated the molecular mechanisms underlying this effect in endothelial cells (ECs). NO production was examined by Griess reagent assay, DAF-2 DA fluorescence staining and cGMP ELISA kits. Protein interaction was determined by western blotting and immunoprecipitation. Treating bovine or human aortic ECs with valsartan increased NO production, as evidenced by elevated level of stable NO metabolites and intracellular cGMP. Valsartan increased the phosphorylation but not the protein level of endothelial NO synthase (eNOS). Inhibition of phosphoinositide-3 kinase (PI3K)/Akt and Src pathways by specific inhibitors suppressed valsartan-induced NO release. In addition, valsartan increased the tyrosine residue phosphorylation of AT(1)R, which was attenuated by inhibition of Src but not PI3K activities. Valsartan also suppressed the interaction of eNOS and AT(1)R, which was blocked by Src or PI3K inhibition. Valsartan-induced NO production in ECs is mediated through Src/PI3K/Akt-dependent phosphorylation of eNOS. Valsartan-induced AT(1)R phosphorylation depends on Src but not PI3K, whereas valsartan-induced suppression of AT(1)R-eNOS interaction depends on Src/PI3K/Akt signalling. These results indicate a novel vasoprotective mechanism of valsartan in upregulating NO production in ECs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据